Exenatide Injection Articles
CHMP positive about exenatide in diabetes
2 October 2006
Stock Commentary - New York week to Aug 28, 2006
4 September 2006
Amylin's 2nd-qtr loss deepens to $46.4M
31 July 2006
Stock Commentary - New York week toJune 26, 2006
3 July 2006
Good 2 yr sugar control on Amylin/Lilly's Byetta
19 June 2006
Development of B-MS' Pargluva discontinued
29 May 2006
Eli Lilly profit up 6% in 1st-qtr 2006
1 May 2006
Stock Commentary - New York week to April 17, 2006
24 April 2006
Stock Commentary - New York week to Mar 20, 2006
27 March 2006
Beyetta diabetes label expansion sought
13 March 2006
Stock Commentary - New York week to Feb 6
13 February 2006
Lilly swings to 4th-qtr 2005 profit
6 February 2006
Amylin buys plant to make Byetta LAR
9 January 2006
Stock Commentary - New York week to Aug 15
5 September 2005
Amylin's 2nd-qtr loss narrows 32% to $26.6M
15 August 2005
Stock Commentary - New York
11 July 2005
Amylin EPS loss inches up 7.5% to $0.43
16 May 2005
Stock Commentary - New York
9 May 2005
Eli Lilly/Amylin's diabetes drug gets FDA OK
9 May 2005
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
